Mutant Sindbis virus E2 glycoprotein (SINV-E2 mutant)

The mutant Sindbis virus E2 glycoprotein is a modified viral surface protein used to pseudotype lentiviral vectors for targeted gene delivery (Yang et al., 2008, Nature Biotechnology). In its wild-type form, the E2 glycoprotein facilitates broad viral entry by binding to ubiquitous receptors like heparan sulfate; however, specific mutations (often referred to as SVGmu) are engineered to ablate this broad tropism and redirect the vector to specific cell types, most notably dendritic cells via the DC-SIGN (CD209) receptor (Lopes et al., 2016, Journal of Immunotherapy). This targeting mechanism is a cornerstone of in vivo dendritic cell programming, where the lentiviral vector carries genetic instructions for tumor-associated antigens directly to the immune system (Immune Design, 2018). This approach is primarily utilized in cancer immunotherapy to elicit a robust T-cell response against specific malignancies, such as those expressing NY-ESO-1 (Pollack et al., 2017, Science Translational Medicine). Therapeutic candidates like LV305 have employed this technology to treat soft tissue sarcomas and other solid tumors (ClinicalTrials.gov, NCT02122861).

Other names

SVGmuSindbis virus envelope protein E2 mutantMutated SINV E2DC-SIGN targeting Sindbis glycoproteinSIN-E2 mutant

The mutant glycoprotein facilitates the selective transduction of DC-SIGN-expressing dendritic cells by a lentiviral vector, enabling the delivery and expression of therapeutic transgenes to initiate a systemic immune response (Yang et al., 2008).